Skip To Main Content
Fausto Barbieri on Muck Rack

Fausto Barbieri

As seen in: Nature, Thorax, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fausto

Contact Fausto, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

|
By Francesco Gelsomino, Marcello Tiseo, Fausto Barbieri, Ferdinando Riccardi
| Nature Verified
Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-020-0845-3, published online 29 April 2020 The original version of this article unfortunately contained a mistake in the affiliation of Dr. Delmonte. The correct affiliation should be: Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. The original article has been corrected.
Open in Who Shared Issue with article?

Pembrolizumab rechallenge in squamous non-small-cell lung cancer and HIV-positivity: a case report

|
By Fausto Barbieri, Monica Barbolini, Giorgia Guaitoli, Eleonora Molinaro
| Future Medicine Verified
Metrics Downloaded 0 times History Received 18 June 2020 Accepted 13 November 2020 Published online 30 November 2020 Information © 2020 Future Medicine Ltd KeywordsFinancial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.
Open in Who Shared Issue with article?

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)

|
By Marcello Tiseo, Francesco Gelsomino, Fausto Barbieri, Ferdinando Riccardi
| Nature Verified
Abstract Background Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study was designed to evaluate activity and safety of nab-paclitaxel in relapsed SCLC.
Open in Who Shared Issue with article?
See all 5 articles